戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 0 or 1750 mg/kg diet), or DHEA + tamoxifen + carbenoxolone.
2 as impaired in the presence of probenecid or carbenoxolone.
3 e inhibitors Brilliant Blue, gadolinium, and carbenoxolone.
4  were blocked by the Cx43 blockers Gap26 and carbenoxolone.
5 harmacological uncoupling with 20-micromol/L carbenoxolone.
6 osphate release inhibitors glibenclamide and carbenoxolone.
7 ion was blocked by the 11beta-HSD2 inhibitor carbenoxolone.
8 eurons via a mechanism that was sensitive to carbenoxolone.
9 s was attenuated by the gap junction blocker carbenoxolone.
10 ing was reversibly blocked by application of carbenoxolone.
11 h were sensitive to the gap junction blocker carbenoxolone.
12  were attenuated by the gap junction blocker carbenoxolone.
13 y by the gap junction inhibitors octanol and carbenoxolone.
14 ith CNQX, AP-5, strychnine, bicuculline, and carbenoxolone.
15         Octanol (260.46 mg or 781.38 mg/kg), carbenoxolone (100 mg/kg), or vehicles were given via in
16       The non-specific gap junction blockers carbenoxolone (100 microM) and octanol (1 mM) attenuated
17         However, the gap junction inhibitors carbenoxolone (100 microM) and palmitoleic acid (50 micr
18                    The gap junction blockers carbenoxolone (100 microm) or octanol (1 mM) significant
19          Gap junction uncouplers (1-octanol, carbenoxolone, 18beta-glycyrrhetinic acid and connexin m
20                                  Addition of carbenoxolone (200 microM), a gap junction channel block
21  to morphine was significantly attenuated by carbenoxolone (25 mg/kg).
22         Partial gap junction uncoupling with carbenoxolone (25 mumol/L) increased focal activity (2.1
23 moxifen (80 or 40 microgram/kg diet), DHEA + carbenoxolone (3500 or 1750 mg/kg diet), or DHEA + tamox
24                                 In addition, carbenoxolone (a gap junction blocker) decreased the cum
25            Spinal (intrathecal) injection of carbenoxolone (a non-selective hemichannel blocker) and
26                                  The IC50 of carbenoxolone, a competitive inhibitor of 11beta-HSD, wa
27 re obtained from crus 2a Purkinje cells, and carbenoxolone, a gap junction blocker, was injected into
28 mitter receptor antagonists and disrupted by carbenoxolone, a gap junction blocker.
29                                  Addition of carbenoxolone, a PANX1 channel blocker, completely aboli
30 normal IO neurons, a finding replicated with carbenoxolone, a pharmacological antagonist of gap junct
31                                              Carbenoxolone abolished all synchronized IPSPs in CA3 ce
32                   The gap junction inhibitor carbenoxolone abolished both electrical and tracer coupl
33 rgic currents, we tested the hypothesis that carbenoxolone acted via specific sites on GABAA receptor
34 lutamate and ATP flux and that the inhibitor carbenoxolone acts from the extracellular side, binding
35                              Neither THA nor carbenoxolone affected electrically stimulated action po
36                                              Carbenoxolone also blocked the isolated synchronized GAB
37                                              Carbenoxolone also depressed responses to exogenous and
38             Likewise, gap junction inhibitor carbenoxolone also inhibited self-assembly of KGN, NHF,
39                       When further examined, Carbenoxolone also led to a significant reduction in inf
40                                              Carbenoxolone also prevented gut wall disruption and sig
41 5, and functional blockade of connexins with carbenoxolone also prevented the in vitro formation of f
42                                              Carbenoxolone also reduced the average firing rate by 50
43 hagocytosis by Hsd11b1(-/-) macrophages, and carbenoxolone, an 11beta-HSD inhibitor, prevented the in
44 exus of the mouse colon; the Cx43 inhibitors carbenoxolone and 43Gap26 inhibited the ability of enter
45        Conversely, the gap junction blockers carbenoxolone and cobalt decreased neuronal CO2/H+ sensi
46                                 By contrast, carbenoxolone and cobalt reduced bright surround, sugges
47                                              Carbenoxolone and cobalt, thought to attenuate feedback
48 e phase, and this increase was suppressed by carbenoxolone and Gap27, and recapitulated by CXCL1.
49 lease was abolished by the channel inhibitor carbenoxolone and inhibited by knockdown of either conne
50            The glycynhetinic acid derivative carbenoxolone and intracellular acidification with CO2 d
51 e in the presence of the pannexin 1 blockers carbenoxolone and probenecid, and the HlyA-induced ATP r
52                               Treatment with carbenoxolone and probenecid, which directly and specifi
53 nc, or AZ 10606120, and by pannexin blockers carbenoxolone and probenecid.
54 us ATP can reverse the inhibitive effects of carbenoxolone and that aggregate compaction is sensitive
55    Cell-to-cell propagation was abolished by carbenoxolone, and was not observed in uncoupled pairs.
56 d that the observed antiepileptic effects of carbenoxolone are likely to be due to blockade of GABAA
57            The administration of octanol and carbenoxolone both failed to attenuate the neurological
58 1 hemichannels with (10)Panx, probenecid, or carbenoxolone but not when connexin hemichannels were in
59                                    Moreover, carbenoxolone caused a reduction in the approximately 10
60 -dione (CNQX) and the gap-junction blockers, carbenoxolone (CBX) and meclofenamic acid (MEC).
61 ats, inhibition of pannexin 1 channels using carbenoxolone (CBX) or Brilliant Blue FCF (BB-FCF) (1-10
62 ely, in CTL hearts, gap junction inhibition (carbenoxolone) decreased coupling and allowed Ca wave-in
63 lockade of gap junctional communication with carbenoxolone did not induce neuronal differentiation in
64 ly administration of a gap junction blocker, carbenoxolone, during the first postnatal week greatly d
65 l inhibitors 18 beta-glycyrrhetinic acid and carbenoxolone, even in cells without physical contact, s
66 ficity of gap junction blockers (18-beta-GA, carbenoxolone, flufenamic acid and heptanol) in paired r
67 unction channel blockers (heptanol, octanol, carbenoxolone, flufenamic acid, and mefloquine) are anta
68 mokine CXCL1, and the release was blocked by carbenoxolone, Gap26/Gap27, and connexin-43 small interf
69                                              Carbenoxolone (IC50 = 2 microM) and 4-methylpyrazole (IC
70 ed cognition, and the nonselective inhibitor carbenoxolone improved verbal memory in elderly men.
71 ft ventricle, left atrium, and right atrium, carbenoxolone increased R(j) by 28+/-9%, 26+/-16%, and 2
72                   The gap junction inhibitor carbenoxolone increases the spontaneous activity of supr
73                      Inhibitor studies using carbenoxolone indicated that blocking innexons resulted
74 icantly affected by the gap junction blocker carbenoxolone, indicating that outward events originated
75 Three independent inhibitors of hemichannels-carbenoxolone, lanthanum and mefloquine-had no significa
76 d La3+) and by gap junction blocking agents (carbenoxolone, octanol, heptanol, flufenamic acid, and 1
77  Reduction in gap junction conductance using carbenoxolone only minimally affected APD distribution i
78 turbing outer retinal signalling with either carbenoxolone or cobalt blocked the effects of the brigh
79  A740003) and Px1 HC blockers ((10)Panx1 and carbenoxolone) prevent the increase in Etd(+) uptake by
80                       Release was blocked by carbenoxolone, probenecid or peptide (10)panx, implicati
81 frequency component of 75.5 +/- 5.6 %, while carbenoxolone produced a reduction of only 14 +/- 42 %.
82 n slowing in vivo in the intact human heart, carbenoxolone prolonged electrogram duration in the righ
83 man and guinea-pig myocardium, pre- and post-carbenoxolone (r(2)=0.946; P<0.01).
84                                              Carbenoxolone reduced CS synchrony by 50% overall, but i
85 drenal gap junctions by the uncoupling agent carbenoxolone reduces nerve stimulation-evoked catechola
86                   Pharmacological testing of Carbenoxolone-related compounds, acting by inhibition of
87 but just a few of these compounds, including Carbenoxolone, remained active when tested in a post-tre
88 nel inhibitors octanol, flufenamic acid, and carbenoxolone significantly blocked spontaneous activity
89 xin/gap junction channels with probenecid or carbenoxolone significantly reduced external dentin stim
90 Population activity was greatly depressed by carbenoxolone, suggesting that propagation of depolarizi
91 ly isolated optic nerve) that was blocked by carbenoxolone, suggesting the existence of functional he
92         Blockade of electrical coupling with carbenoxolone suppressed amplitude, frequency and half-w
93 he connexin 43 (Cx43) mimetic peptide Gap26, carbenoxolone, the pannexin1 (Panx1) mimetic peptide (10
94 suppression was inhibited by the addition of carbenoxolone to cocultures, suggesting that gap junctio
95             We used the gap junction blocker carbenoxolone to investigate the role of electrotonic co
96 al administration of the 11betaHSD inhibitor carbenoxolone to uremic rats for 2 wk improved glucose t
97 blished gap junction inhibitors: octonal and carbenoxolone, to interrupt cell to cell communication w
98 s accompanied by a decline in TEP1 levels in carbenoxolone-treated mosquitoes.
99                                      Lastly, carbenoxolone was found to reverse or prevent changes in
100                                              Carbenoxolone washout restored activity.
101  and sensitive to the gap junction inhibitor carbenoxolone, whereas the effect on electrical activity
102 f 18beta-glycyrrhetinic acid (18beta-GA) and carbenoxolone, which have been shown to block electrical

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top